Skip to main navigation
Vaxxinity logo
  • Overview
  • News Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Governance Overview
    • Board of Directors
    • Our Team
    • Committee Composition
  • Financials
    • SEC Filings
    • Quarterly Results
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

News Releases

12 Jan '22
Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
DALLAS, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first patient with Parkinson’s disease (PD) has been dosed with UB-312 in Part B of a double-blinded,
10 Jan '22
Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Support UB-312 Vaccine Study
DALLAS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a clinical-stage biotech company pioneering a new class of immunotherapeutic vaccines to treat and prevent chronic neurological diseases, including Alzheimer’s and Parkinson’s, has announced that the company has been awarded
04 Jan '22
Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors
DALLAS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the appointment of Jason Pesile, MBA, CPA, as Senior Vice President, Finance & Accounting.

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Print Page
  • Email Alerts
  • RSS Feeds
  • Contact IR
Copyright © 2022 Vaxxinity | Privacy Policy